Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Effects of Metformin on Cellular Proliferation and Steroid Hormone Receptors in Patient-Derived, Low-Grade Endometrial Cancer Cell Lines.

Collins G, Mesiano S, DiFeo A.

Reprod Sci. 2018 Jan 1:1933719118779734. doi: 10.1177/1933719118779734. [Epub ahead of print]

PMID:
29848180
2.

Mitotic Exit dysfunction through the deregulation of APC/C characterizes cisplatin resistant state in epithelial ovarian cancer.

Belur Nagaraj A, Kovalenko O, Avelar RA, Joseph P, Brown A, Surti A, Mantilla S, DiFeo A.

Clin Cancer Res. 2018 Apr 13. pii: clincanres.2885.2017. doi: 10.1158/1078-0432.CCR-17-2885. [Epub ahead of print]

PMID:
29653924
3.

Corrigendum: Positively selected enhancer elements endow osteosarcoma cells with metastatic competence.

Morrow JJ, Bayles I, Funnell APW, Miller TE, Saiakhova A, Lizardo MM, Bartels CF, Kapteijn MY, Hung S, Mendoza A, Dhillon G, Chee DR, Myers JT, Allen F, Gambarotti M, Righi A, DiFeo A, Rubin BP, Huang AY, Meltzer PS, Helman LJ, Picci P, Versteeg HH, Stamatoyannopoulos JA, Khanna C, Scacheri PC.

Nat Med. 2018 Apr 10;24(4):525. doi: 10.1038/nm0418-525c.

PMID:
29634688
4.

Small-Molecule Activators of Protein Phosphatase 2A for the Treatment of Castration-Resistant Prostate Cancer.

McClinch K, Avelar RA, Callejas D, Izadmehr S, Wiredja D, Perl A, Sangodkar J, Kastrinsky DB, Schlatzer D, Cooper M, Kiselar J, Stachnik A, Yao S, Hoon D, McQuaid D, Zaware N, Gong Y, Brautigan DL, Plymate SR, Sprenger CCT, Oh WK, Levine AC, Kirschenbaum A, Sfakianos JP, Sears R, DiFeo A, Ioannou Y, Ohlmeyer M, Narla G, Galsky MD.

Cancer Res. 2018 Apr 15;78(8):2065-2080. doi: 10.1158/0008-5472.CAN-17-0123. Epub 2018 Jan 22.

PMID:
29358171
5.

Positively selected enhancer elements endow osteosarcoma cells with metastatic competence.

Morrow JJ, Bayles I, Funnell APW, Miller TE, Saiakhova A, Lizardo MM, Bartels CF, Kapteijn MY, Hung S, Mendoza A, Dhillon G, Chee DR, Myers JT, Allen F, Gambarotti M, Righi A, DiFeo A, Rubin BP, Huang AY, Meltzer PS, Helman LJ, Picci P, Versteeg HH, Stamatoyannopoulos JA, Khanna C, Scacheri PC.

Nat Med. 2018 Feb;24(2):176-185. doi: 10.1038/nm.4475. Epub 2018 Jan 15. Erratum in: Nat Med. 2018 Apr 10;24(4):525.

PMID:
29334376
6.

Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment.

Nagaraj AB, Wang QQ, Joseph P, Zheng C, Chen Y, Kovalenko O, Singh S, Armstrong A, Resnick K, Zanotti K, Waggoner S, Xu R, DiFeo A.

Oncogene. 2018 Jan 18;37(3):403-414. doi: 10.1038/onc.2017.328. Epub 2017 Oct 2.

7.

CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors.

Saygin C, Wiechert A, Rao VS, Alluri R, Connor E, Thiagarajan PS, Hale JS, Li Y, Chumakova A, Jarrar A, Parker Y, Lindner DJ, Nagaraj AB, Kim JJ, DiFeo A, Abdul-Karim FW, Michener C, Rose PG, DeBernardo R, Mahdi H, McCrae KR, Lin F, Lathia JD, Reizes O.

J Exp Med. 2017 Sep 4;214(9):2715-2732. doi: 10.1084/jem.20170438. Epub 2017 Aug 24.

8.

Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.

Sangodkar J, Perl A, Tohme R, Kiselar J, Kastrinsky DB, Zaware N, Izadmehr S, Mazhar S, Wiredja DD, O'Connor CM, Hoon D, Dhawan NS, Schlatzer D, Yao S, Leonard D, Borczuk AC, Gokulrangan G, Wang L, Svenson E, Farrington CC, Yuan E, Avelar RA, Stachnik A, Smith B, Gidwani V, Giannini HM, McQuaid D, McClinch K, Wang Z, Levine AC, Sears RC, Chen EY, Duan Q, Datt M, Haider S, Ma'ayan A, DiFeo A, Sharma N, Galsky MD, Brautigan DL, Ioannou YA, Xu W, Chance MR, Ohlmeyer M, Narla G.

J Clin Invest. 2017 Jun 1;127(6):2081-2090. doi: 10.1172/JCI89548. Epub 2017 May 15.

9.

InFlo: a novel systems biology framework identifies cAMP-CREB1 axis as a key modulator of platinum resistance in ovarian cancer.

Dimitrova N, Nagaraj AB, Razi A, Singh S, Kamalakaran S, Banerjee N, Joseph P, Mankovich A, Mittal P, DiFeo A, Varadan V.

Oncogene. 2017 Apr 27;36(17):2472-2482. doi: 10.1038/onc.2016.398. Epub 2016 Nov 7.

10.

A prognostic regulatory pathway in stage I epithelial ovarian cancer: new hints for the poor prognosis assessment.

Calura E, Paracchini L, Fruscio R, DiFeo A, Ravaggi A, Peronne J, Martini P, Sales G, Beltrame L, Bignotti E, Tognon G, Milani R, Clivio L, Dell'Anna T, Cattoretti G, Katsaros D, Sartori E, Mangioni C, Ardighieri L, D'Incalci M, Marchini S, Romualdi C.

Ann Oncol. 2016 Aug;27(8):1511-9. doi: 10.1093/annonc/mdw210. Epub 2016 May 18.

PMID:
27194815
11.

Altered glutamine metabolism in platinum resistant ovarian cancer.

Hudson CD, Savadelis A, Nagaraj AB, Joseph P, Avril S, DiFeo A, Avril N.

Oncotarget. 2016 Jul 5;7(27):41637-41649. doi: 10.18632/oncotarget.9317.

12.

Cisplatin induces stemness in ovarian cancer.

Wiechert A, Saygin C, Thiagarajan PS, Rao VS, Hale JS, Gupta N, Hitomi M, Nagaraj AB, DiFeo A, Lathia JD, Reizes O.

Oncotarget. 2016 May 24;7(21):30511-22. doi: 10.18632/oncotarget.8852.

13.

Identification of high-grade serous ovarian cancer miRNA species associated with survival and drug response in patients receiving neoadjuvant chemotherapy: a retrospective longitudinal analysis using matched tumor biopsies.

Petrillo M, Zannoni GF, Beltrame L, Martinelli E, DiFeo A, Paracchini L, Craparotta I, Mannarino L, Vizzielli G, Scambia G, D'Incalci M, Romualdi C, Marchini S.

Ann Oncol. 2016 Apr;27(4):625-34. doi: 10.1093/annonc/mdw007. Epub 2016 Jan 17.

PMID:
26782955
14.

RNF126 promotes homologous recombination via regulation of E2F1-mediated BRCA1 expression.

Wang Y, Deng O, Feng Z, Du Z, Xiong X, Lai J, Yang X, Xu M, Wang H, Taylor D, Yan C, Chen C, Difeo A, Ma Z, Zhang J.

Oncogene. 2016 Mar 17;35(11):1363-72. doi: 10.1038/onc.2015.198. Epub 2015 Aug 3.

15.

Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.

Nagaraj AB, Joseph P, Kovalenko O, Singh S, Armstrong A, Redline R, Resnick K, Zanotti K, Waggoner S, DiFeo A.

Oncotarget. 2015 Sep 15;6(27):23720-34.

16.

miRNAs as prognostic and therapeutic tools in epithelial ovarian cancer.

Nagaraj AB, Joseph P, DiFeo A.

Biomark Med. 2015;9(3):241-57. doi: 10.2217/bmm.14.108. Review.

PMID:
25731210
17.

Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease.

Sivendran S, Chang R, Pham L, Phelps RG, Harcharik ST, Hall LD, Bernardo SG, Moskalenko MM, Sivendran M, Fu Y, de Moll EH, Pan M, Moon JY, Arora S, Cohain A, DiFeo A, Ferringer TC, Tismenetsky M, Tsui CL, Friedlander PA, Parides MK, Banchereau J, Chaussabel D, Lebwohl MG, Wolchok JD, Bhardwaj N, Burakoff SJ, Oh WK, Palucka K, Merad M, Schadt EE, Saenger YM.

J Invest Dermatol. 2014 Aug;134(8):2202-2211. doi: 10.1038/jid.2014.85. Epub 2014 Feb 12.

18.

Crowdsourcing awareness: exploration of the ovarian cancer knowledge gap through Amazon Mechanical Turk.

Carter RR, DiFeo A, Bogie K, Zhang GQ, Sun J.

PLoS One. 2014 Jan 22;9(1):e85508. doi: 10.1371/journal.pone.0085508. eCollection 2014.

19.

microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition.

Parikh A, Lee C, Joseph P, Marchini S, Baccarini A, Kolev V, Romualdi C, Fruscio R, Shah H, Wang F, Mullokandov G, Fishman D, D'Incalci M, Rahaman J, Kalir T, Redline RW, Brown BD, Narla G, DiFeo A.

Nat Commun. 2014;5:2977. doi: 10.1038/ncomms3977.

20.

Drug Intervention Response Predictions with PARADIGM (DIRPP) identifies drug resistant cancer cell lines and pathway mechanisms of resistance.

Brubaker D, Difeo A, Chen Y, Pearl T, Zhai K, Bebek G, Chance M, Barnholtz-Sloan J.

Pac Symp Biocomput. 2014:125-35.

21.

Multiple breast cancer cell-lines derived from a single tumor differ in their molecular characteristics and tumorigenic potential.

Mosoyan G, Nagi C, Marukian S, Teixeira A, Simonian A, Resnick-Silverman L, DiFeo A, Johnston D, Reynolds SR, Roses DF, Mosoian A.

PLoS One. 2013;8(1):e55145. doi: 10.1371/journal.pone.0055145. Epub 2013 Jan 25.

22.

KLF6-SV1 drives breast cancer metastasis and is associated with poor survival.

Hatami R, Sieuwerts AM, Izadmehr S, Yao Z, Qiao RF, Papa L, Look MP, Smid M, Ohlssen J, Levine AC, Germain D, Burstein D, Kirschenbaum A, DiFeo A, Foekens JA, Narla G.

Sci Transl Med. 2013 Jan 23;5(169):169ra12. doi: 10.1126/scitranslmed.3004688.

23.

A new feature of the MYH9-related syndrome: chronic transaminase elevation.

Favier R, DiFeo A, Hezard N, Fabre M, Bedossa P, Martignetti JA.

Hepatology. 2013 Mar;57(3):1288-9. doi: 10.1002/hep.25913. Epub 2012 Nov 27. No abstract available.

PMID:
22806255
24.

Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response.

Sangodkar J, Dhawan NS, Melville H, Singh VJ, Yuan E, Rana H, Izadmehr S, Farrington C, Mazhar S, Katz S, Albano T, Arnovitz P, Okrent R, Ohlmeyer M, Galsky M, Burstein D, Zhang D, Politi K, Difeo A, Narla G.

J Clin Invest. 2012 Jul;122(7):2637-51. doi: 10.1172/JCI62058. Epub 2012 Jun 1.

25.

Ligand-dependent corepressor (LCoR) recruitment by Kruppel-like factor 6 (KLF6) regulates expression of the cyclin-dependent kinase inhibitor CDKN1A gene.

Calderon MR, Verway M, An BS, DiFeo A, Bismar TA, Ann DK, Martignetti JA, Shalom-Barak T, White JH.

J Biol Chem. 2012 Mar 16;287(12):8662-74. doi: 10.1074/jbc.M111.311605. Epub 2012 Jan 25.

26.

Phosphorylation of the myosin IIA tailpiece regulates single myosin IIA molecule association with lytic granules to promote NK-cell cytotoxicity.

Sanborn KB, Mace EM, Rak GD, Difeo A, Martignetti JA, Pecci A, Bussel JB, Favier R, Orange JS.

Blood. 2011 Nov 24;118(22):5862-71. doi: 10.1182/blood-2011-03-344846.

27.

The first report of homozygous May-Hegglin anomaly E1841K mutation.

Poopak B, Rezvani H, Difeo A, Martignetti JA, Khosravipour G, Yousefian A, Farahani K, Haghnejad Doshanlo F, Saki N.

Eur J Haematol. 2011 Apr;86(4):357. doi: 10.1111/j.1600-0609.2010.01553.x. Epub 2011 Jan 11. No abstract available.

PMID:
21083612
28.

Nucleo-cytoplasmic localization domains regulate Krüppel-like factor 6 (KLF6) protein stability and tumor suppressor function.

Rodríguez E, Aburjania N, Priedigkeit NM, DiFeo A, Martignetti JA.

PLoS One. 2010 Sep 9;5(9). pii: e12639. doi: 10.1371/journal.pone.0012639.

29.

Loss of matrix metalloproteinase-2 amplifies murine toxin-induced liver fibrosis by upregulating collagen I expression.

Radbill BD, Gupta R, Ramirez MC, DiFeo A, Martignetti JA, Alvarez CE, Friedman SL, Narla G, Vrabie R, Bowles R, Saiman Y, Bansal MB.

Dig Dis Sci. 2011 Feb;56(2):406-16. doi: 10.1007/s10620-010-1296-0. Epub 2010 Jun 19.

30.

Emerging roles of Kruppel-like factor 6 and Kruppel-like factor 6 splice variant 1 in ovarian cancer progression and treatment.

DiFeo A, Narla G, Martignetti JA.

Mt Sinai J Med. 2009 Dec;76(6):557-66. doi: 10.1002/msj.20150. Review.

31.

Myosin IIA associates with NK cell lytic granules to enable their interaction with F-actin and function at the immunological synapse.

Sanborn KB, Rak GD, Maru SY, Demers K, Difeo A, Martignetti JA, Betts MR, Favier R, Banerjee PP, Orange JS.

J Immunol. 2009 Jun 1;182(11):6969-84. doi: 10.4049/jimmunol.0804337.

32.

KLF6-SV1 is a novel antiapoptotic protein that targets the BH3-only protein NOXA for degradation and whose inhibition extends survival in an ovarian cancer model.

Difeo A, Huang F, Sangodkar J, Terzo EA, Leake D, Narla G, Martignetti JA.

Cancer Res. 2009 Jun 1;69(11):4733-41. doi: 10.1158/0008-5472.CAN-08-4282. Epub 2009 May 12.

33.

Ribosome-inactivating proteins isolated from dietary bitter melon induce apoptosis and inhibit histone deacetylase-1 selectively in premalignant and malignant prostate cancer cells.

Xiong SD, Yu K, Liu XH, Yin LH, Kirschenbaum A, Yao S, Narla G, DiFeo A, Wu JB, Yuan Y, Ho SM, Lam YW, Levine AC.

Int J Cancer. 2009 Aug 15;125(4):774-82. doi: 10.1002/ijc.24325. Erratum in: Int J Cancer. 2009 Oct 15;125(8):1995.

34.

Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma.

Sangodkar J, DiFeo A, Feld L, Bromberg R, Schwartz R, Huang F, Terzo EA, Choudhri A, Narla G.

Lung Cancer. 2009 Dec;66(3):292-7. doi: 10.1016/j.lungcan.2009.02.014. Epub 2009 Mar 28.

35.

Systemic hyalinosis mutations in the CMG2 ectodomain leading to loss of function through retention in the endoplasmic reticulum.

Deuquet J, Abrami L, Difeo A, Ramirez MC, Martignetti JA, van der Goot FG.

Hum Mutat. 2009 Apr;30(4):583-9. doi: 10.1002/humu.20872.

PMID:
19191226
36.

Functional role of the KLF6 tumour suppressor gene in gastric cancer.

Sangodkar J, Shi J, DiFeo A, Schwartz R, Bromberg R, Choudhri A, McClinch K, Hatami R, Scheer E, Kremer-Tal S, Martignetti JA, Hui A, Leung WK, Friedman SL, Narla G.

Eur J Cancer. 2009 Mar;45(4):666-76. doi: 10.1016/j.ejca.2008.11.009. Epub 2008 Dec 26.

37.

The role of KLF6 and its splice variants in cancer therapy.

DiFeo A, Martignetti JA, Narla G.

Drug Resist Updat. 2009 Feb-Apr;12(1-2):1-7. doi: 10.1016/j.drup.2008.11.001. Epub 2008 Dec 18. Review.

PMID:
19097929
38.

KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis.

Narla G, DiFeo A, Fernandez Y, Dhanasekaran S, Huang F, Sangodkar J, Hod E, Leake D, Friedman SL, Hall SJ, Chinnaiyan AM, Gerald WL, Rubin MA, Martignetti JA.

J Clin Invest. 2008 Aug;118(8):2711-21. doi: 10.1172/JCI34780.

39.

A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response.

DiFeo A, Feld L, Rodriguez E, Wang C, Beer DG, Martignetti JA, Narla G.

Cancer Res. 2008 Feb 15;68(4):965-70. doi: 10.1158/0008-5472.CAN-07-2604. Epub 2008 Feb 4.

40.

KLF6 allelic loss is associated with tumor recurrence and markedly decreased survival in head and neck squamous cell carcinoma.

Teixeira MS, Camacho-Vanegas O, Fernandez Y, Narla G, DiFeo A, Lee B, Kalir T, Friedman SL, Schlecht NF, Genden EM, Urken M, Brandwein-Gensler M, Martignetti JA.

Int J Cancer. 2007 Nov 1;121(9):1976-83.

41.

Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma.

Camacho-Vanegas O, Narla G, Teixeira MS, DiFeo A, Misra A, Singh G, Chan AM, Friedman SL, Feuerstein BG, Martignetti JA.

Int J Cancer. 2007 Sep 15;121(6):1390-5.

42.

Loss of MMP-2 disrupts skeletal and craniofacial development and results in decreased bone mineralization, joint erosion and defects in osteoblast and osteoclast growth.

Mosig RA, Dowling O, DiFeo A, Ramirez MC, Parker IC, Abe E, Diouri J, Aqeel AA, Wylie JD, Oblander SA, Madri J, Bianco P, Apte SS, Zaidi M, Doty SB, Majeska RJ, Schaffler MB, Martignetti JA.

Hum Mol Genet. 2007 May 1;16(9):1113-23. Epub 2007 Mar 30.

43.

Torg-Winchester syndrome: lack of efficacy of pamidronate therapy.

Phadke SR, Ramirez M, Difeo A, Martignetti JA, Girisha KM.

Clin Dysmorphol. 2007 Apr;16(2):95-100.

PMID:
17351352
44.

Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation.

Kremer-Tal S, Narla G, Chen Y, Hod E, DiFeo A, Yea S, Lee JS, Schwartz M, Thung SN, Fiel IM, Banck M, Zimran E, Thorgeirsson SS, Mazzaferro V, Bruix J, Martignetti JA, Llovet JM, Friedman SL.

J Hepatol. 2007 Apr;46(4):645-54. Epub 2006 Nov 27.

45.

[The MYH9 syndrome: report of a new case with a new mutation of the MYH9 gene].

Schleinitz N, Favier R, Mazodier K, Difeo A, Ebbo M, Veit V, Berda-Haddad Y, Bernit E, Heudier P, Kaplanski G, Camoin L, Bardet V, Harle JR.

Rev Med Interne. 2006 Oct;27(10):783-6. Epub 2006 Aug 15. French.

PMID:
16978745
46.

Bladder exstrophy and Epstein type congenital macrothrombocytopenia: evidence for a common cause?

Utsch B, DiFeo A, Kujat A, Karle S, Schuster V, Lenk H, Jacobs U, Müller M, Dötsch J, Rascher W, Reutter H, Martignetti JA, Ludwig M, Tröbs RB.

Am J Med Genet A. 2006 Oct 15;140(20):2251-3. No abstract available.

PMID:
16969870
47.

Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination.

DiFeo A, Narla G, Hirshfeld J, Camacho-Vanegas O, Narla J, Rose SL, Kalir T, Yao S, Levine A, Birrer MJ, Bonome T, Friedman SL, Buller RE, Martignetti JA.

Clin Cancer Res. 2006 Jun 15;12(12):3730-9.

48.

E-cadherin is a novel transcriptional target of the KLF6 tumor suppressor.

DiFeo A, Narla G, Camacho-Vanegas O, Nishio H, Rose SL, Buller RE, Friedman SL, Walsh MJ, Martignetti JA.

Oncogene. 2006 Sep 28;25(44):6026-31. Epub 2006 May 15.

PMID:
16702959
49.

KLF6 is one transcription factor involved in regulating acid ceramidase gene expression.

Park JH, Eliyahu E, Narla G, DiFeo A, Martignetti JA, Schuchman EH.

Biochim Biophys Acta. 2005 Dec 30;1732(1-3):82-7. Epub 2006 Jan 26.

PMID:
16500425
50.

Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread.

Narla G, DiFeo A, Yao S, Banno A, Hod E, Reeves HL, Qiao RF, Camacho-Vanegas O, Levine A, Kirschenbaum A, Chan AM, Friedman SL, Martignetti JA.

Cancer Res. 2005 Jul 1;65(13):5761-8.

Supplemental Content

Support Center